• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.

    6/4/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    • Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance
    • Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patients
    • Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy

    BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026.

    Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)

    "Last week's FDA clearance of our updated 5008X CAREsystem with additional features was a critical milestone in our work to improve the lives of people living with kidney disease by bringing industry-leading, high-volume hemodiafiltration dialysis therapy to the U.S.", said Helen Giza, CEO for Fresenius Medical Care AG. "Hemodiafiltration is already the treatment standard across much of Europe, Latin America, and Asia, and we are very well experienced with it. Our great familiarity with this treatment, combined with the outcome and promising results of the external CONVINCE* research study, reiterated the significant patient health and well-being benefits available with high-volume hemodiafiltration. With this additional clearance, we now begin the next steps of our national U.S. rollout by deploying the machine to a first wave of Fresenius Kidney Care clinics for the remainder of 2025 and continuing broadly across the U.S. in 2026 and beyond. It's a landmark moment in the industry. We will set the new standard of kidney care in the U.S."

    Fresenius Medical Care first received 510(k) clearance for its 5008X CAREsystem in February 2024, which allowed the company to conduct focused testing, clinical evaluations, and user-studies of the device in a pilot clinic. Last week's May 2025 FDA 510(k) notice provided clearance for an updated 5008X CAREsystem with additional features, including the Fresenius Clinical Data Exchange® (CDX), a unique Fresenius Medical Care technology built into the 5008X that enables ONE-TOUCH access to providers' medical information systems (MIS) directly at chairside without the need for additional computer stations. By providing direct access to providers' MIS, the CDX helps to optimize clinic workflows, reduce the risk of cross contamination and CMS V-tag citations, and open up clinic space by reducing computer and cabling clutter.

    Beginning in a few months and continuing through the remainder of the year, Fresenius Medical Care's Care Delivery patient care business segment will begin offering hemodiafiltration dialysis therapy in selected first wave clinics across regions in its U.S. Fresenius Kidney Care dialysis clinics. In the U.S. there is an estimated installed base of around 160,000 in-center hemodialysis machines across all service providers that could be replaced to adapt this new standard of care.

    The 5008X CAREsystem is one of Fresenius Medical Care's latest medical device innovations. Along with the companion FX CorAL® dialyzer – approved by FDA –, the 5008X CAREsystem combines the latest device engineering and cutting-edge membrane technologies that facilitate high-volume hemodiafiltration with many additional workflow and therapy improvements possible.

    The results of the groundbreaking CONVINCE* study demonstrated that patients treated with high-volume hemodiafiltration experienced a remarkable 23% decrease in mortality rates compared to those treated with the more commonly used high-flux hemodialysis. Funded by the European Union, the CONVINCE study was a multinational research study that compared these two types of hemodialysis techniques in a three-year trial performed at 61 dialysis centers in eight European countries.

    About Fresenius Medical Care:

    Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,674 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

    For more information visit the company's website at www.freseniusmedicalcare.com.

    *Funded by the European Union, conducted by the CONVINCE consortium, and led by the University Medical Center Utrecht, the international, randomized controlled CONVINCE trial marked a crucial milestone in comparing high-volume hemodiafiltration with standard, high-flux hemodialysis.

    The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission's opinions.

    The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).

    Disclaimer:

    This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

    Media contact

    Christine Peters

    T +49 160 60 66 770

    [email protected]

    Emanuela Cariolagian

    T +1 213 706 0051

    [email protected]

    Contact for analysts and investors

    Dr. Dominik Heger

    T +49 6172 609 2601

    [email protected]

    www.freseniusmedicalcare.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-begins-broader-us-commercialization-of-5008x-caresystem-achieves-key-milestones-in-efforts-to-introduce-high-volume-hemodiafiltration-dialysis-therapy-to-individuals-with-kidney-disease-in-the-us-302472825.html

    SOURCE Fresenius Medical Care Holdings, Inc.

    Get the next $FMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    9/2/2025Neutral → Sell
    UBS
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    More analyst ratings

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

    Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care EnablementAs part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year endBAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.

    10/1/25 9:35:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

    Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance benefits of the vertical integration and accelerate value creation in line with the FME Reignite strategyBAD HOMBURG, Germany, Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, to

    9/18/25 3:30:00 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

    Total volume of the initial share buyback is up to EUR 1 billion over two yearsShare buyback to take place until August 10, 2027BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.

    8/11/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical downgraded by UBS

    UBS downgraded Fresenius Medical from Neutral to Sell

    9/2/25 8:32:54 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical upgraded by BofA Securities

    BofA Securities upgraded Fresenius Medical from Underperform to Neutral

    12/2/24 8:51:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Berenberg initiated coverage on Fresenius Medical with a new price target

    Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

    11/6/24 6:26:23 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    10/1/25 11:12:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    9/19/25 7:31:33 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/11/25 7:34:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    View All

    Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

    Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care EnablementAs part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year endBAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.

    10/1/25 9:35:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

    Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance benefits of the vertical integration and accelerate value creation in line with the FME Reignite strategyBAD HOMBURG, Germany, Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, to

    9/18/25 3:30:00 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

    Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

    3/13/24 10:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

    FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

    6/17/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

    Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

    5/22/25 11:45:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

    SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

    12/7/23 11:45:52 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care